Legal
Legal and claims statement
What this website says, and what it does not say.
No health claims. Alcyon makes no claim that any product prevents, treats, cures, mitigates or reduces the risk of norovirus infection or of any other disease or condition.
1. Status of the programme
Alcyon is at the research and development stage. No Alcyon product is on the market and none has received regulatory authorisation in any jurisdiction. The regulatory route under investigation is a food-supplement-first strategy. It is not confirmed and remains subject to review by qualified regulatory counsel.
2. How content on this site is labelled
Statements on this site fall into three categories, and the wording follows the category:
Established science
Publicly established facts, such as norovirus biology or what IgY and OMVs are. Written with "is" and "does".
Designed capability
What the platform is designed or intended to do. Not a statement that it has been shown to do so.
Exploratory Exploratory
Planned or exploratory work. Written with "would", "may" or "is being investigated", and always badged.
3. Data and results
The programme's data are prospective. No experimental, preclinical or clinical result is reported on this site. Any measurement methods described explain how evidence will be generated, not what it has shown. Laboratory assays described here, including attachment-blocking assays, do not establish neutralisation, mucosal immunity, prevention, treatment, symptom reduction or reduced viral shedding.
4. Not medical advice
Nothing on this site is medical advice, and it should not be used to make decisions about health. Passive immunity is not a vaccine and is not a substitute for one. Anyone with health concerns should consult a qualified healthcare professional.
5. Allergens
IgY is recovered from egg yolk and is an egg-derived material. Any future product based on it would not be intended for people with egg allergy.
6. Forward-looking statements
Programme timelines, stages and plans described on this site are forward-looking. They depend on research outcomes, funding, partners and regulatory advice, and may change without notice.
7. Intellectual property
Names, marks, text and figures on this site belong to Alcyon S.A. unless stated otherwise. Technical summaries are shared with partners under appropriate confidentiality terms.
8. Entity
Alcyon S.A. · registered address, company number and contact email to be confirmed
Last updated: November 2026. Subject to review by regulatory counsel before publication.